Initial Approval Date: January 20, 2021

CRITERIA FOR PRIOR AUTHORIZATION

Brand Medical Necessity Prior Authorization

BILLING CODE TYPE For drug coverage and provider type information, see the KMAP Reference Codes webpage.

MANUAL GUIDELINES Prior authorization will be required for all active drugs that are multi-source brand products.

GENERAL CRITERIA FOR INITIAL PRIOR AUTHORIZATION: (must meet all of the following)

- Dispensing of generic medications* are required. Exceptions will be made when no authorized generics exist AND the prescriber provides details of at least ONE of the following:
 - Serious Adverse reaction or allergic reaction to a generic product that meets at least ONE of the following:
 - Rash or hives**
 - Life threatening
 - Hospitalization
 - Disability
 - Required intervention to prevent impairment or damage.
 - Therapeutic failure that is supported by laboratory confirmation of suboptimal drug plasma concentrations when compared to published pharmacokinetic profiles for the brand name drug (or reference-listed drug).

Note: Patient must use an authorized generic (if one exists), instead of the brand-name product.

*Generic medications include:

- All therapeutically equivalent products or interchangeable biologic products as found in the FDA's publication Approved Drug Products with Therapeutic Equivalence Evaluations (also known as the Orange Book) or the Database of Licensed Biological Products (also known as the Purple Book).
- Authorized generics, such as those that are filed under the same new drug application (NDA) or biologics license application (BLA) with the FDA.

LENGTH OF APPROVAL: Lifetime (for the specified product), unless an authorized generic becomes available.

Drug Utilization Review Committee Chair	PHARMACY PROGRAM MANAGER
	DIVISION OF HEALTH CARE FINANCE
	Kansas Department of Health and Environment
	 Date

^{**}Applies only when the rash or hives would not otherwise be expected to occur in the brand product.